Vericel Corporation (VCEL)

$45.22

-1.88

(-3.99%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $44.91
    $47.40
    $45.22
    downward going graph

    0.69%

    Downside

    Day's Volatility :5.25%

    Upside

    4.6%

    downward going graph
  • $30.18
    $54.10
    $45.22
    downward going graph

    33.26%

    Downside

    52 Weeks Volatility :44.21%

    Upside

    16.41%

    downward going graph

Returns

PeriodVericel CorporationSector (Health Care)Index (Russel 2000)
3 Months
1.89%
5.1%
0.0%
6 Months
0.89%
4.9%
0.0%
1 Year
37.49%
16.6%
0.0%
3 Years
-19.34%
13.2%
-22.3%

Highlights

Market Capitalization
2.2B
Book Value
$4.97
Earnings Per Share (EPS)
0.01
PE Ratio
4522.0
PEG Ratio
0.0
Wall Street Target Price
57.25
Profit Margin
0.37%
Operating Margin TTM
-11.45%
Return On Assets TTM
-0.7%
Return On Equity TTM
0.36%
Revenue TTM
214.5M
Revenue Per Share TTM
4.46
Quarterly Revenue Growth YOY
14.7%
Gross Profit TTM
109.8M
EBITDA
1.2M
Diluted Eps TTM
0.01
Quarterly Earnings Growth YOY
1.05
EPS Estimate Current Year
0.1
EPS Estimate Next Year
0.53
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.03

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Vericel Corporation(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.6%

Current $45.22
Target $57.25

Company Financials

FY18Y/Y Change
Revenue
90.9M
↑ 42.13%
Net Income
-8.1M
↓ 52.93%
Net Profit Margin
-8.96%
↑ 18.08%
FY19Y/Y Change
Revenue
117.9M
↑ 29.71%
Net Income
-7.9M
↓ 2.8%
Net Profit Margin
-6.71%
↑ 2.25%
FY20Y/Y Change
Revenue
124.2M
↑ 5.37%
Net Income
2.9M
↓ 136.21%
Net Profit Margin
2.31%
↑ 9.02%
FY21Y/Y Change
Revenue
156.2M
↑ 25.77%
Net Income
-7.5M
↓ 360.86%
Net Profit Margin
-4.78%
↓ 7.09%
FY22Y/Y Change
Revenue
164.4M
↑ 5.24%
Net Income
-16.7M
↑ 123.65%
Net Profit Margin
-10.17%
↓ 5.39%
FY23Y/Y Change
Revenue
197.5M
↑ 20.17%
Net Income
-3.2M
↓ 80.96%
Net Profit Margin
-1.61%
↑ 8.56%
Q1 FY23Q/Q Change
Revenue
41.0M
↓ 22.16%
Net Income
-6.3M
↓ 207.01%
Net Profit Margin
-15.45%
↓ 26.69%
Q2 FY23Q/Q Change
Revenue
45.9M
↑ 11.96%
Net Income
-5.0M
↓ 20.78%
Net Profit Margin
-10.93%
↑ 4.52%
Q3 FY23Q/Q Change
Revenue
45.6M
↓ 0.74%
Net Income
-3.7M
↓ 27.09%
Net Profit Margin
-8.03%
↑ 2.9%
Q4 FY23Q/Q Change
Revenue
65.0M
↑ 42.59%
Net Income
13.0M
↓ 455.0%
Net Profit Margin
19.99%
↑ 28.02%
Q1 FY24Q/Q Change
Revenue
51.3M
↓ 21.1%
Net Income
-3.9M
↓ 129.72%
Net Profit Margin
-7.53%
↓ 27.52%
Q2 FY24Q/Q Change
Revenue
52.7M
↑ 2.69%
Net Income
-4.7M
↑ 21.23%
Net Profit Margin
-8.89%
↓ 1.36%
FY18Y/Y Change
Total Assets
118.7M
↑ 117.47%
Total Liabilities
16.5M
↓ 48.63%
FY19Y/Y Change
Total Assets
153.2M
↑ 29.11%
Total Liabilities
42.1M
↑ 156.09%
FY20Y/Y Change
Total Assets
205.6M
↑ 34.18%
Total Liabilities
71.3M
↑ 69.28%
FY21Y/Y Change
Total Assets
243.7M
↑ 18.53%
Total Liabilities
73.2M
↑ 2.66%
FY22Y/Y Change
Total Assets
273.0M
↑ 12.02%
Total Liabilities
80.7M
↑ 10.22%
FY23Y/Y Change
Total Assets
353.7M
↑ 29.54%
Total Liabilities
127.7M
↑ 58.19%
Q1 FY23Q/Q Change
Total Assets
265.1M
↓ 2.9%
Total Liabilities
71.1M
↓ 11.91%
Q2 FY23Q/Q Change
Total Assets
310.7M
↑ 17.21%
Total Liabilities
111.8M
↑ 57.18%
Q3 FY23Q/Q Change
Total Assets
318.1M
↑ 2.39%
Total Liabilities
113.7M
↑ 1.76%
Q4 FY23Q/Q Change
Total Assets
353.7M
↑ 11.17%
Total Liabilities
127.7M
↑ 12.27%
Q1 FY24Q/Q Change
Total Assets
356.7M
↑ 0.85%
Total Liabilities
122.8M
↓ 3.87%
Q2 FY24Q/Q Change
Total Assets
376.8M
↑ 5.66%
Total Liabilities
133.9M
↑ 9.04%
FY18Y/Y Change
Operating Cash Flow
-412.0K
↓ 96.87%
Investing Cash Flow
-67.0M
↑ 4338.87%
Financing Cash Flow
58.9M
↑ 216.86%
FY19Y/Y Change
Operating Cash Flow
-7.2M
↑ 1643.45%
Investing Cash Flow
10.6M
↓ 115.84%
Financing Cash Flow
5.3M
↓ 91.06%
FY20Y/Y Change
Operating Cash Flow
17.6M
↓ 344.63%
Investing Cash Flow
-17.2M
↓ 261.66%
Financing Cash Flow
6.4M
↑ 22.45%
FY21Y/Y Change
Operating Cash Flow
29.0M
↑ 65.26%
Investing Cash Flow
-3.5M
↓ 79.6%
Financing Cash Flow
9.2M
↑ 42.38%
FY22Y/Y Change
Operating Cash Flow
17.7M
↓ 39.09%
Investing Cash Flow
-36.2M
↑ 934.16%
Financing Cash Flow
1.0M
↓ 88.61%
Q1 FY23Q/Q Change
Operating Cash Flow
7.9M
↑ 12.69%
Investing Cash Flow
2.8M
↓ 112.89%
Financing Cash Flow
107.0K
↓ 82.31%
Q2 FY23Q/Q Change
Operating Cash Flow
10.2M
↑ 29.72%
Investing Cash Flow
-2.4M
↓ 186.0%
Financing Cash Flow
1.2M
↑ 1016.82%

Technicals Summary

Sell

Neutral

Buy

Vericel Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vericel Corporation
Vericel Corporation
-0.2%
0.89%
37.49%
-19.34%
184.76%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vericel Corporation
Vericel Corporation
4522.0
4522.0
0.0
0.1
0.0
-0.01
NA
4.97
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vericel Corporation
Vericel Corporation
Buy
$2.2B
184.76%
4522.0
0.37%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Vericel Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 51.28M → 52.66M (in $), with an average increase of 2.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 12.99M → -4.68M (in $), with an average decrease of 75.5% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 88.5%

Institutional Holdings

  • BlackRock Inc

    16.43%

  • Brown Capital Management, LLC

    9.01%

  • Vanguard Group Inc

    7.03%

  • State Street Corporation

    6.56%

  • FMR Inc

    4.79%

  • Conestoga Capital Advisors, LLC

    4.16%

Company Information

about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea

Organization
Vericel Corporation
Employees
314
CEO
Mr. Dominick C. Colangelo Esq.
Industry
Health Technology

Discover More

FAQs